Patents by Inventor Peter Law

Peter Law has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230040299
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: August 25, 2022
    Publication date: February 9, 2023
    Inventors: Dominique Amans, Stephen John Atkinson, Lee Andrew Harrison, David Jonathan Hirst, Robert Peter Law, Matthew Lindon, Alexander Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
  • Patent number: 11478478
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: October 25, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Dominique Amans, Stephen John Atkinson, Lee Andrew Harrison, David Jonathan Hirst, Robert Peter Law, Matthew Lindon, Alexander Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
  • Publication number: 20210046073
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: January 7, 2020
    Publication date: February 18, 2021
    Inventors: Dominique Amans, Stephen John Atkinson, Lee Andrew Harrison, David Jonathan Hirst, Robert Peter Law, Matthew Lindon, Alexander Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
  • Patent number: 10583139
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: March 10, 2020
    Inventors: Dominique Amans, Stephen John Atkinson, Lee Andrew Harrison, David Jonathan Hirst, Robert Peter Law, Matthew Lindon, Alexander Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
  • Patent number: 10166368
    Abstract: An autonomously controllable pull wire injection 5 catheter 1 and a method for operating the same are provided. The catheter 1 includes an outer catheter guide 2, 33 having an outer catheter guide casing 39 and an inner operating catheter 3, 31 having an inner operating catheter casing 16, wherein the inner operating catheter 3, 31 includes a catheter handle 30, a catheter tip 10, at least one needle 5 that is connected to at least one source of medicinal solution via at least one needle 10 channel 4, 26, at least one contact force sensor 9a-f, 25, at least one electrode 7, 24, at least four actuator driven pull wires 12-15, 20-23 for moving the tip 10 of the inner operating catheter 3, 31.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: January 1, 2019
    Inventor: Peter Law
  • Publication number: 20180303831
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: June 25, 2018
    Publication date: October 25, 2018
    Inventors: Dominique AMANS, Stephen John ATKINSON, Lee Andrew HARRISON, David Jonathan HIRST, Robert Peter LAW, Matthew LINDON, Alexander PRESTON, Jonathan Thomas SEAL, Christopher Roland WELLAWAY
  • Patent number: 10034881
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: July 31, 2018
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Dominique Amans, Stephen John Atkinson, Lee Andrew Harrison, David Jonathan Hirst, Robert Peter Law, Matthew Lindon, Alexander Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
  • Publication number: 20180078739
    Abstract: An autonomously controllable pull wire injection 5 catheter 1 and a method for operating the same are provided. The catheter 1 includes an outer catheter guide 2, 33 having an outer catheter guide casing 39 and an inner operating catheter 3, 31 having an inner operating catheter casing 16, wherein the inner operating catheter 3, 31 includes a catheter handle 30, a catheter tip 10, at least one needle 5 that is connected to at least one source of medicinal solution via at least one needle 10 channel 4, 26, at least one contact force sensor 9a-f, 25, at least one electrode 7, 24, at least four actuator driven pull wires 12-15, 20-23 for moving the tip 10 of the inner operating catheter 3, 31.
    Type: Application
    Filed: September 21, 2017
    Publication date: March 22, 2018
    Inventor: Peter LAW
  • Publication number: 20170189401
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: March 23, 2017
    Publication date: July 6, 2017
    Inventors: Dominique AMANS, Stephen John ATKINSON, Lee Andrew HARRISON, David Jonathan HIRST, Robert Peter LAW, Matthew LINDON, Alexander PRESTON, Jonathan Thomas SEAL, Christopher Roland WELLAWAY
  • Patent number: 9637456
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: May 2, 2017
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Dominique Amans, Stephen John Atkinson, Lee Andrew Harrison, David Jonathan Hirst, Robert Peter Law, Matthew Lindon, Alexander Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
  • Publication number: 20160016908
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: March 12, 2014
    Publication date: January 21, 2016
    Applicant: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Dominique AMANS, Stephen John ATKINSON, Lee Andrew HARRISON, David Jonathan HIRST, Robert Peter LAW, Matthew LINDON, Alexander PRESTON, Jonathan Thomas SEAL, Christopher Roland WELLAWAY
  • Patent number: 8831512
    Abstract: An apparatus and method is disclosed to negotiate communications parameters between near field communications (NFC) capable devices. In some embodiments, the NFC capable devices operate in a negotiation phase to negotiate one or more communications parameters prior to transferring information. In other embodiments, the NFC capable devices simultaneously negotiate the one or more communications parameters with the transferring of the information.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: September 9, 2014
    Assignee: Broadcom Corporation
    Inventors: Peter Laws, John Waters
  • Publication number: 20130005244
    Abstract: An apparatus and method is disclosed to negotiate communications parameters between near field communications (NFC) capable devices. In some embodiments, the NFC capable devices operate in a negotiation phase to negotiate one or more communications parameters prior to transferring information. In other embodiments, the NFC capable devices simultaneously negotiate the one or more communications parameters with the transferring of the information.
    Type: Application
    Filed: June 28, 2011
    Publication date: January 3, 2013
    Applicant: BROADCOM CORPORATION
    Inventors: Peter LAWS, John Waters
  • Publication number: 20120283409
    Abstract: Embodiments of the present invention include methods and systems for designing inhibitors of amyloidosis in humans, domesticated animals, and wild animals as well as inhibitors of amyloidosis designed by the methods and systems. Methods and systems for designing inhibitors of amyloidosis are largely computational, in nature, and are directed to designing various types of polymers, small-molecule organic compounds, organometallic compounds, or non-chemical physical processes that can target the extended-?-strand and ?-sheet regions of amyloidogenic protein and polypeptide intermediates in order to prevent aggregation of those intermediates into protofibrils and fibrils that, in turn, recruit additional native-conformation proteins and polypeptides into amyloidogenic intermediates and that additionally aggregate to form higher-order structures, such as plaques observed in the brains of patients suffering from the various spongiform encephalopathies.
    Type: Application
    Filed: July 17, 2012
    Publication date: November 8, 2012
    Applicant: UNIVERSITY OF WASHINGTON
    Inventors: Valerie Daggett, Peter Law
  • Patent number: 8242241
    Abstract: Embodiments of the present invention include methods and systems for designing inhibitors of amyloidosis in humans, domesticated animals, and wild animals as well as inhibitors of amyloidosis designed by the methods and systems. Methods and systems for designing inhibitors of amyloidosis are largely computational, in nature, and are directed to designing various types of polymers, small-molecule organic compounds, organometallic compounds, or non-chemical physical processes that can target the extended-?-strand and ?-sheet regions of amyloidogenic protein and polypeptide intermediates in order to prevent aggregation of those intermediates into protofibrils and fibrils that, in turn, recruit additional native-conformation proteins and polypeptides into amyloidogenic intermediates and that additionally aggregate to form higher-order structures, such as plaques observed in the brains of patients suffering from the various spongiform encephalopathies.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: August 14, 2012
    Assignee: University of Washington
    Inventors: Valerie Daggett, Peter Law
  • Publication number: 20090248379
    Abstract: Embodiments of the present invention include methods and systems for designing inhibitors of amyloidosis in humans, domesticated animals, and wild animals as well as inhibitors of amyloidosis designed by the methods and systems. Methods and systems for designing inhibitors of amyloidosis are largely computational, in nature, and are directed to designing various types of polymers, small-molecule organic compounds, organometallic compounds, or non-chemical physical processes that can target the extended-?-strand and ?-sheet regions of amyloidogenic protein and polypeptide intermediates in order to prevent aggregation of those intermediates into protofibrils and fibrils that, in turn, recruit additional native-conformation proteins and polypeptides into amyloidogenic intermediates and that additionally aggregate to form higher-order structures, such as plaques observed in the brains of patients suffering from the various spongiform encephalopathies.
    Type: Application
    Filed: March 27, 2008
    Publication date: October 1, 2009
    Inventors: Valerie Daggett, Peter Law
  • Publication number: 20070009499
    Abstract: Bioengineering the regenerative heart or other body organ in need of greater muscle mass or improved blood perfusion provides a novel treatment for organ weakness or failure. In the case of cardiac failure treatment, on May 14, 2002, a 55-year-old man suffering ischemic myocardial infarction received 25 injections carrying 465 million cGMP-produced pure myoblasts into his myocardium after coronary artery bypass grafting. Three myogenesis mechanisms were elucidated with 17 human/porcine xenografts using cyclosporine as immunosuppressant. Some myoblasts developed to become cardiomyocytes. Others transferred their nuclei into host cardiomyocytes through natural cell fusion. As yet others formed skeletal myofibers with satellite cells. De novo production of contractile filaments augmented heart contractility. Human myoblasts transduced with VEGF165 gene produced six times more capillaries in porcine myocardium than placebo.
    Type: Application
    Filed: February 28, 2006
    Publication date: January 11, 2007
    Inventor: Peter Law
  • Publication number: 20060104961
    Abstract: Bioengineering the regenerative heart provides a novel treatment for heart failure. On May 14, 2002, a 55-year-old man suffering ischemic myocardial infarction received 25 injections carrying 465 million cGMP-produced pure myoblasts into his myocardium after coronary artery bypass grafting. Three myogenesis mechanisms were elucidated with 17 human/porcine xenografts using cyclosporine as immunosuppressant. Some myoblasts developed to become cardiomyocytes. Others transferred their nuclei into host cardiomyocytes through natural cell fusion. As yet others formed skeletal myofibers with satellite cells. De novo production of contractile filaments augmented heart contractility. Human myoblasts transduced with VEGF165 gene produced six times more capillaries in porcine myocardium than placebo. Xenograft rejection was not observed for up to 20 weeks despite cyclosporine discontinuation at 6 weeks.
    Type: Application
    Filed: August 6, 2003
    Publication date: May 18, 2006
    Inventor: Peter Law
  • Publication number: 20060057119
    Abstract: Muscle cell materials and methods are provided for refurbishing skin. Skin surfaces are prepared by removing dead cells and myoblasts are added in a cell-nutritive solution. An embodiment provides autologous human myoblast cells from the individual to be treated, serum from the individual, and an angiogenesis factor for stimulation of vascularization. Large 6 chondroitin sulfate may be used for controlled rapid cell fusion of the myoblasts. Foreskin fibroblast cell suspensions also may be used singly or in combination with myoblasts. In yet another embodiment non-immunogenic cells from another animal such as a pig with a double knockout mutation that affects foreign recognition may be added to cell surfaces.
    Type: Application
    Filed: August 19, 2003
    Publication date: March 16, 2006
    Inventor: Peter Law
  • Publication number: 20050244384
    Abstract: Myoblast cells obtained by culturing, particularly from satellite cells or other progenitor cells, are transplanted into tissue such as diseased heart tissue to form healthy repair tissue and reverse disease. This technique can be carried out in various ways and preferably includes a cellular integration factor to assist cellular survival, integration and longevity into the treated organ. Angiogenesis factors such as vascular endothelial growth factor are particularly preferred and may be transgenically expressed by the transplanted cell. Other factors that may be used to augment the procedure include migratory and scaffolding molecules. The methods and materials are particularly useful in combination with an automated cell processor and an automated catheter delivery system. The materials and methods for their use may be applied to the prophylaxis and therapy of damaged hearts, using cells originally obtained from the patient, another human, or another animal.
    Type: Application
    Filed: March 31, 2003
    Publication date: November 3, 2005
    Inventor: Peter Law